While Gilead (NASDAQ:GILD) is often thought of as king in the HIV space and is leading the race for successful interferon-free hepatitis C treatment with some astounding cure rates in clinical trials, its recent announcement that it will acquire YM BioSciences (UNKNOWN:YMI.DL) highlights a lesser-known direction for the company: its oncology pipeline. In this video, Motley Fool health care analyst David Williamson discusses what the acquisition means for Gilead and its aspirations in the oncology field.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid

The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.